AR092318A1 - TOBRAMYCIN FORMULATION - Google Patents

TOBRAMYCIN FORMULATION

Info

Publication number
AR092318A1
AR092318A1 ARP130101588A ARP130101588A AR092318A1 AR 092318 A1 AR092318 A1 AR 092318A1 AR P130101588 A ARP130101588 A AR P130101588A AR P130101588 A ARP130101588 A AR P130101588A AR 092318 A1 AR092318 A1 AR 092318A1
Authority
AR
Argentina
Prior art keywords
formulation
tobramycin
tobramycin formulation
mosmol
osmolarity
Prior art date
Application number
ARP130101588A
Other languages
Spanish (es)
Inventor
Higham David
Hawkins Kevin
Original Assignee
Norton Healthcare Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GBGB1208080.0A external-priority patent/GB201208080D0/en
Application filed by Norton Healthcare Ltd filed Critical Norton Healthcare Ltd
Publication of AR092318A1 publication Critical patent/AR092318A1/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
    • A61K31/7034—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
    • A61K31/7036—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin having at least one amino group directly attached to the carbocyclic ring, e.g. streptomycin, gentamycin, amikacin, validamycin, fortimicins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A61K9/0078—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy for inhalation via a nebulizer such as a jet nebulizer, ultrasonic nebulizer, e.g. in the form of aqueous drug solutions or dispersions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • General Chemical & Material Sciences (AREA)
  • Molecular Biology (AREA)
  • Dispersion Chemistry (AREA)
  • Otolaryngology (AREA)
  • Pulmonology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)

Abstract

Una formulación de solución farmacéutica que comprende tobramicina, agua, cloruro de sodio y citrato de sodio, en donde la formulación tiene un pH de 4,5 - 7,0 y una osmolaridad de 135 - 200 mOsmol/Kg, proceso y uso. Reivindicación 9: Una formulación de acuerdo con cualquiera de las reivindicaciones precedentes, caracterizado por el tratamiento de la infección causada por Pseudomonas aeruginosa, particularmente en pacientes con fibrosis quística.A pharmaceutical solution formulation comprising tobramycin, water, sodium chloride and sodium citrate, wherein the formulation has a pH of 4.5-7.0 and an osmolarity of 135-200 mOsmol / Kg, process and use. Claim 9: A formulation according to any of the preceding claims, characterized by the treatment of infection caused by Pseudomonas aeruginosa, particularly in patients with cystic fibrosis.

ARP130101588A 2012-05-09 2013-05-08 TOBRAMYCIN FORMULATION AR092318A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201261644700P 2012-05-09 2012-05-09
GBGB1208080.0A GB201208080D0 (en) 2012-05-09 2012-05-09 Tobramycin formulation

Publications (1)

Publication Number Publication Date
AR092318A1 true AR092318A1 (en) 2015-04-15

Family

ID=48428414

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP130101588A AR092318A1 (en) 2012-05-09 2013-05-08 TOBRAMYCIN FORMULATION

Country Status (2)

Country Link
AR (1) AR092318A1 (en)
SM (1) SMT201500031B (en)

Also Published As

Publication number Publication date
SMT201500031B (en) 2015-05-05

Similar Documents

Publication Publication Date Title
PE20170183A1 (en) STABLE NON-COMPLEX IODINE COMPOSITIONS AND METHODS OF USE
CL2015000574A1 (en) Stable aqueous formulations of adalimumab.
BR112018075140A2 (en) composition in the form of an injectable aqueous solution, and single dose formulation at a pH of 7 to 7.8
DOP2016000298A (en) PIRAZOLOPIRIDINAS AND PIRAZOLOPIRIMIDINAS
CL2015003690A1 (en) Use of pridopidine or a salt thereof to prepare a medication useful in the treatment of huntington's disease.
CO7141410A2 (en) Nitrogenous heterocyclic compound
AR084285A1 (en) IMMUNOGENIC COMPOSITIONS
CL2010001406A1 (en) Ophthalmic pharmaceutical composition comprising povidone iodine, and a steroidal anti-inflammatory compound, a non-steroidal anti-inflammatory compound, an antibacterial, an anti-allergic or an anti-glaucoma compound; and method to preserve the composition.
BR112015000520A2 (en) stable lipase thickening agent
ECSP11011076A (en) TREATMENT OF COGNITIVE DISORDERS WITH (R) -7-CHLORINE-N- (QUINUCLIDIN-3-IL) BENZO [B] THIOPHEN-2-CARBOXAMIDE AND PHARMACEUTICALLY ACCEPTABLE SALTS OF THE SAME
NZ603345A (en) Stabilized ophthalmic galactomannan formulations
MY182507A (en) Aqueous ophthalmic solution
AR098168A1 (en) STABLE FORMULATION OF GLULISINE INSULIN
UY35988A (en) PROCESS FOR THE PRODUCTION OF AN INJECTABLE LOW CONCENTRATION NORADRENALINE SOLUTION
FR2984170B1 (en) DECONTAMINATION GEL AND METHOD OF DECONTAMINATING SURFACES BY SOAKING USING THE GEL.
AR088585A1 (en) A MEDICINAL PRODUCT TO TREAT THE PREVIOUS EYE DISEASE
CL2012003168A1 (en) Pharmaceutical composition comprising an aqueous solution of minocycline and a divalent or trivalent cation in a ratio greater than 2: 1 with respect to the minocycline; Preparation method; kit and use in the treatment of bacterial infections.
DOP2014000252A (en) (R) -Nifuratel, its Use for the Treatment of Infections and Synthesis of (R) and (S) -Nifuratel
AR101581A1 (en) COLUTORY COMPOSITION
AR088016A1 (en) ABSORBENT ARTICLE
PE20130374A1 (en) PHARMACEUTICAL COMPOSITION INCLUDING IBUPROFEN
UY34796A (en) TOBRAMYCIN FORMULATION
PE20151543A1 (en) ORAL PHARMACEUTICAL COMPOSITION OF SULPHATE SALTS FOR DUAL USE TABLETS AND METHODS FOR ITS USE
AR092318A1 (en) TOBRAMYCIN FORMULATION
ES2530751T3 (en) Tobramycin formulation

Legal Events

Date Code Title Description
FB Suspension of granting procedure